A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf
.
Metabolomic Biomarkers for Detection, Prognosis and Identifying Recurrence in Endometrial Cancer
2020
Metabolites
Metabolic reprogramming is increasingly recognised as one of the defining hallmarks of tumorigenesis. There is compelling evidence to suggest that endometrial cancer develops and progresses in the context of profound metabolic dysfunction. Whilst the incidence of endometrial cancer continues to rise in parallel with the global epidemic of obesity, there are, as yet, no validated biomarkers that can aid risk prediction, early detection, prognostic evaluation or surveillance. Advances in
doi:10.3390/metabo10080314
pmid:32751940
pmcid:PMC7463916
fatcat:u234bxhjrnfzdpocms5zmgxqxm